Biotech Values

[genisi]

Factoid: Teva has the lowest P/E ratio* of any consistently profitable drug/biotech company.

Corollary: Most investors don’t think thrice-weekly Copaxone is likely to be an effective lifecycle-management fix for the Copaxone franchise, as Teva contends.

Investors don't think Teva's strategy as a whole is convincing: its intention to focus on New Therapeutic Entity (NTE), no mention of exciting program in the pipeline, etc.